- Report
- August 2024
- 138 Pages
Global
From €2729EUR$2,999USD£2,340GBP
- Report
- April 2025
- 200 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- January 2024
- 73 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
Melphalan is a chemotherapy drug used to treat certain types of leukemia, including multiple myeloma and non-Hodgkin's lymphoma. It is a type of alkylating agent, which works by interfering with the growth of cancer cells. It is usually given intravenously, but can also be taken orally. Melphalan is often used in combination with other drugs, such as prednisone, to increase its effectiveness.
Melphalan is a widely used drug in the treatment of leukemia, and is available in both generic and brand-name formulations. It is typically prescribed by oncologists and hematologists, and is available in both oral and intravenous forms.
The market for Melphalan is highly competitive, with many companies offering their own formulations of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and Teva Pharmaceuticals. Show Less Read more